Cowen began coverage on shares of Generation Bio (NASDAQ:GBIO) in a research report report published on Tuesday morning, BenzingaRatingsTable reports. The firm issued an outperform rating on the stock.
Separately, Jefferies Financial Group assumed coverage on Generation Bio in a report on Tuesday. They set a buy rating and a $38.00 price target for the company.
GBIO opened at $19.71 on Tuesday. Generation Bio has a twelve month low of $18.51 and a twelve month high of $24.90.
Generation Bio Company Profile
Generation Bio Co develops gene therapies for the treatment of genetic diseases. It focuses in the areas of liver, eye, muscle, and brain disorders. Generation Bio Co was formerly known as Torus Therapeutics, Inc and changed its name to Generation Bio Co in November 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.
Featured Article: What economic reports are most valuable to investors?
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.